DK0828758T3 - Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering - Google Patents

Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering

Info

Publication number
DK0828758T3
DK0828758T3 DK96914826T DK96914826T DK0828758T3 DK 0828758 T3 DK0828758 T3 DK 0828758T3 DK 96914826 T DK96914826 T DK 96914826T DK 96914826 T DK96914826 T DK 96914826T DK 0828758 T3 DK0828758 T3 DK 0828758T3
Authority
DK
Denmark
Prior art keywords
grf
pro
chimeric
grf analogs
adipose
Prior art date
Application number
DK96914826T
Other languages
Danish (da)
English (en)
Inventor
Michel Ibea
Paul Brazeau
Thierry Abribat
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27036979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0828758(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Application granted granted Critical
Publication of DK0828758T3 publication Critical patent/DK0828758T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
DK96914826T 1995-05-26 1996-05-22 Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering DK0828758T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45306795A 1995-05-26 1995-05-26
US65164596A 1996-05-22 1996-05-22
PCT/CA1996/000327 WO1996037514A1 (en) 1995-05-26 1996-05-22 Chimeric fatty body-pro-grf analogs with increased biological potency

Publications (1)

Publication Number Publication Date
DK0828758T3 true DK0828758T3 (da) 2002-01-07

Family

ID=27036979

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96914826T DK0828758T3 (da) 1995-05-26 1996-05-22 Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering

Country Status (13)

Country Link
US (2) US5939386A (de)
EP (1) EP0828758B1 (de)
JP (1) JP3576170B2 (de)
KR (1) KR100543190B1 (de)
AT (1) ATE204881T1 (de)
AU (1) AU697119B2 (de)
BR (2) BRPI9608799B8 (de)
CA (1) CA2222068C (de)
DE (1) DE69614849T2 (de)
DK (1) DK0828758T3 (de)
ES (1) ES2163020T3 (de)
PT (1) PT828758E (de)
WO (1) WO1996037514A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
EP1052286A3 (de) * 1999-04-12 2001-07-25 Pfizer Products Inc. Wachstumshormon- (GH) und Wachstumshormon-freisetzenden Hormon (GHRH) enthaltende Zusammensetzungen
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
CN1454214A (zh) * 2000-08-02 2003-11-05 赛莱技术公司 具有增高功效的修饰生物肽
EP1205551A1 (de) * 2000-11-09 2002-05-15 Pfizer Products Inc. Wachstumshormon- (GH) und Wachstumshormon-freisetzenden Hormon (GHRH) enthaltende Zusammensetzungen
FR2851461B1 (fr) * 2003-02-21 2007-04-20 Seppic Sa Utilisation de n-octanoyl aminoacides comme actif cosmetique et pharmaceutique amincissant
WO2004105789A1 (en) * 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
EP2274978B1 (de) 2003-09-12 2015-05-20 Tercica, Inc. Verfahren zur Behandlung von IGF-1 (insulin-like growth factor 1)-Mangel
CA2542433A1 (en) * 2003-10-20 2005-04-28 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
US20130261058A1 (en) * 2010-09-16 2013-10-03 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
KR20140027284A (ko) 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 성장 호르몬 방출 인자(grf) 유사체 및 이의 용도
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
EP2819688A4 (de) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazol- und thioethervernetzte peptidomimetische makrozyklen
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
CN102702343A (zh) * 2012-06-14 2012-10-03 吉尔生化（上海）有限公司 一种固相合成替莫瑞林的方法
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US8871713B2 (en) 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
EP3197478A4 (de) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017181277A1 (en) 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
EP4608388A1 (de) * 2022-10-25 2025-09-03 Starrock Pharma Inc. Kombinatorische und rotierende kombinatorische therapien für adipositas und andere erkrankungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1271600A (en) * 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
DE3742633A1 (de) * 1987-12-16 1989-06-29 Hoechst Ag Peptide mit beeinflussender wirkung auf die hypophyse von saeugern
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated growth hormone-releasing peptides and use thereof
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ZA922746B (en) * 1991-04-26 1992-12-30 Lilly Co Eli Superactive grf analogs

Also Published As

Publication number Publication date
JP3576170B2 (ja) 2004-10-13
ATE204881T1 (de) 2001-09-15
ES2163020T3 (es) 2002-01-16
AU697119B2 (en) 1998-09-24
BR9608799A (pt) 1999-12-07
DE69614849T2 (de) 2002-05-16
CA2222068C (en) 2007-04-10
US5861379A (en) 1999-01-19
BRPI9608799B8 (pt) 2019-11-05
WO1996037514A1 (en) 1996-11-28
AU5683396A (en) 1996-12-11
MX9709098A (es) 1998-06-30
KR19990021938A (ko) 1999-03-25
EP0828758B1 (de) 2001-08-29
JPH11505807A (ja) 1999-05-25
DE69614849D1 (de) 2001-10-04
BR9608799B1 (pt) 2009-12-01
EP0828758A1 (de) 1998-03-18
CA2222068A1 (en) 1996-11-28
PT828758E (pt) 2002-02-28
KR100543190B1 (ko) 2006-06-23
US5939386A (en) 1999-08-17

Similar Documents

Publication Publication Date Title
DK0828758T3 (da) Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
ATE311453T1 (de) Grf-analoge mit erhöhter biologischer potenz
ATE494902T1 (de) Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums
HU9400495D0 (en) Peptides having growth hormone releasing activity
ATE76296T1 (de) Pharmazeutische zusammensetzung zur behandlung von akuter myocardischer ischaemie.
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
EP1027359A4 (de) Monozyklische l-nukleoside, analoga und ihre anwendungen
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
HK16492A (en) Pharmaceutical compositions of somatostatin analogues
DK193887D0 (da) Fysiologisk aktivt peptid
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
FI886019A7 (fi) Laastari vaikuttavien aineiden valvotusti jakamiseksi iholle
GR3005612T3 (de)
SE8008415L (sv) Cyklisk analog for fagocytosstimulerande naturpeptid, dvs treonyl-cyklo-(-n-lysyl-prolyl-arginyl-)
GR3023038T3 (en) Use of coconut precursor fatty acid as insect-repellent.
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
PL297850A1 (en) Polypeptide compounds ehibiting activity capable to release the growth hormone
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
ES2124235T3 (es) Uso de tri(n-butil) fosfato a bajo ph en soluciones de proteinas biologicamente activas para mejorar la actividad viricida.
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
DE3771057D1 (de) Platin enthaltender cytostatischer wirkstoff.
ATE39697T1 (de) Erythromycin-a-salz mit mucosecretolytischer und fluidisierender aktivitaet, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
UA19786A (uk) Засіб для обробки бульб кортоплі перед посадкою